Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 10 of 100 as at 31 Oct 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Apimeds Pharmaceuticals US, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (95): Smaller than most of the companies we track.
Volatility (5): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on APUS, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
APUS appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 81% of US stocks
Cheaper than 20% of US stocks
Cheaper than 69% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 40% of US stocks
Higher than 34% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Apimeds Pharmaceuticals US, Inc. has a market value of $4.5M and an enterprise value of $10.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$58.2M.
Free cash flow in the twelve months to 30 June 2026: −$13.3M.
Trailing P/E: −0.5×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Apimeds Pharmaceuticals US, Inc. employs 2 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Apimeds Pharmaceuticals US, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
NILA Token is scheduled to begin trading on Pionex on Wednesday, Oct. 14, 2026, at 6 a.m. ET. The exchange is described as global and as offering built-in automated trading bots.
Why it matters — The announcement concerns a cryptocurrency listing and does not state a direct connection to Apimeds Pharmaceuticals US, Inc.
MindWave Innovations, a wholly owned subsidiary of Apimeds Pharmaceuticals US (APUS), signed a 12-month software development and technology services agreement with New York-based Flash Sports & Media Holdings to build and operate FlashChain, a blockchain for tracking digital broadcasting rights, video assets and match ticket inventory. This marks MindWave's second agreement expanding its U.S. commercial footprint.
Why it matters — APUS watchers would care because this second U.S. commercial agreement signals continued growth in MindWave's blockchain technology business under the APUS umbrella.
Apimeds Pharmaceuticals US Inc. shares surged Thursday after its wholly owned subsidiary, MindWave Innovations Inc., announced a 12-month technology services agreement with Singapore-based AQUAE Holdings Pte. Ltd. to build and operate AQUAEChain.
Why it matters — A new commercial technology services deal through the company's subsidiary could expand Apimeds' business beyond its core pharmaceutical operations.
MindWave Innovations announced an agreement to build and operate AQUAEChain, a platform for insured ALCI credits. MindWave will supply and operate the technology, while AQUAE leads the ALCI Credits methodology, brand, and market development.
Why it matters — This item concerns an unrelated technology partnership and has no apparent bearing on Apimeds Pharmaceuticals US, Inc. (APUS).
IBN announced that it has initiated coverage of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS), which has engaged IBN to assist with its corporate communications strategy. The announcement was made via GlobeNewsWire from Austin, Texas.
Why it matters — APUS watchers may gain increased visibility and communication support for the company through this newly engaged financial news and publishing relationship.
As at 31 Oct 2026, Apimeds Pharmaceuticals US, Inc. ranks 10 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).
No analyst covering Apimeds Pharmaceuticals US, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APUS are extrapolating price history, which says nothing about the business.
Apimeds Pharmaceuticals US Inc. is a clinical-stage biopharmaceutical company focused on developing Apitox, a purified bee venom-based therapeutic candidate delivered intradermally.
The most recent item we track (GlobeNewsWire, 13 Oct 2026): "NILA Token to Begin Trading on Pionex, Opening Access to Eligible Users Worldwide". NILA Token is scheduled to begin trading on Pionex on Wednesday, Oct. 14, 2026, at 6 a.m. ET. The exchange is described as global and as offering built-in automated trading bots.
Apimeds Pharmaceuticals US Inc. is a clinical-stage biopharmaceutical company focused on developing Apitox, a purified bee venom-based therapeutic candidate delivered intradermally. The company is primarily working on treatments for inflammation and pain management, with an emphasis on knee osteoarthritis and, to a lesser extent, multiple sclerosis. Its current business centers on advancing this non-narcotic drug candidate through clinical development and related pharmaceutical activities. Apimeds Pharmaceuticals US Inc. also operates as part of a broader biopharmaceutical platform that includes research, development, and potential commercialization capabilities. Headquartered in Matawan, New Jersey, the company is positioned within the specialty drug manufacturing and biotechnology markets, where its work targets high-need conditions in musculoskeletal and inflammatory care.
CEO Dr. Vinod Menon · 2 employees · United States · https://www.mindwavedao.com